Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of British Columbia
Kivu Bioscience Inc.
University of California, San Francisco
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
University of Alabama at Birmingham
MOMA Therapeutics
Kestrel Therapeutics, Inc.
Mersana Therapeutics
Canadian Cancer Trials Group
Corcept Therapeutics
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Context Therapeutics Inc.
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC
AstraZeneca
Mayo Clinic
National Cancer Institute (NCI)
Parabilis Medicines, Inc.
National Institutes of Health Clinical Center (CC)
Jazz Pharmaceuticals
University of Florida
Compass Therapeutics
Bayer
AstraZeneca
Eikon Therapeutics
Genmab
Fate Therapeutics
Epsilogen Ltd
Memorial Sloan Kettering Cancer Center
Alliance Foundation Trials, LLC.
BioNTech SE
AstraZeneca
Boehringer Ingelheim
IDEAYA Biosciences
Radiopharm Theranostics, Ltd
Peking University People's Hospital
Avera McKennan Hospital & University Health Center
858 Therapeutics, Inc.
Radiopharm Theranostics, Ltd
Radboud University Medical Center
Whitehawk Therapeutics, Inc.
3D Medicines
Imperial College London
Memorial Sloan Kettering Cancer Center
Acrivon Therapeutics